title: Physician and patient survey of allergic rhinitis in France: perceptions on prevalence, severity of symptoms, care management and specific immunotherapy.
abstract: BACKGROUND
  Specific immunotherapy (SIT) is the only aetiological treatment used in allergic rhinitis (AR). A telephone survey of patients and physicians in France was carried out to understand better the real and perceived advantages and inconveniences of this therapeutic approach.
  
  
  METHODS
  A cohort of 453 individuals with AR was selected using the Score For Allergic Rhinitis questionnaire. The survey evaluated the level of understanding of allergic rhinitis and its management, including both pharmacotherapy and SIT. A parallel survey was conducted with 400 general practitioners, allergists and nonallergist specialists.
  
  
  RESULTS
  Approximately 50% of patients had heard about SIT as a therapeutic option. Of these, 56% had a positive view of SIT and 14% a negative image. A majority of patients and physicians with a positive opinion associated SIT with improved well-being and quality of life, while those with a negative opinion considered it to be a long and inconvenient treatment, with uncertain results. Over 50% of patients who had been offered SIT had accepted it and approximately 60% of these were satisfied with it. The future availability of SIT as sublingual tablets was perceived positively by both patients and physicians.
  
  
  CONCLUSIONS
  Many patients with AR are unaware of their pathology and few seek help from health professionals. When patients take medication, they are generally satisfied with their treatment, even if it is only symptomatic. Patients and physicians see the notion of definitive recovery as the main benefit of SIT, whereas the main disadvantage is the duration of treatment.
authors.affiliation: Unité d'Exploration des Allergies, INSERM U657 Hôpital Arnaud de Villeneuve, Montpellier, France.
authors.forename: P
authors.initials: P
authors.lastname: Demoly
authors.forename: A
authors.initials: A
authors.lastname: Didier
authors.forename: P
authors.initials: P
authors.lastname: Mathelier-Fusade
authors.forename: M
authors.initials: M
authors.lastname: Drouet
authors.forename: M
authors.initials: M
authors.lastname: David
authors.forename: G
authors.initials: G
authors.lastname: Bonnelye
authors.forename: J de
authors.initials: Jd
authors.lastname: Blic
authors.forename: J M
authors.initials: JM
authors.lastname: Klossek
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005602:France; D006306:Health Surveys; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D015995:Prevalence; D006255:Rhinitis, Allergic, Seasonal / Q000453:epidemiology* / Q000628:therapy*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome